Changing R&D models in research-based pharmaceutical companies

New drugs serving unmet medical needs are one of the key value drivers of research-based pharmaceutical companies. The efficiency of research and development (R&D), defined as the successful approval and launch of new medicines (output) in the rate of the monetary investments required for R&...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuhmacher, Alexander, Gassmann, Oliver, Hinder, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847363/
https://www.ncbi.nlm.nih.gov/pubmed/27118048
http://dx.doi.org/10.1186/s12967-016-0838-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847363/
https://www.ncbi.nlm.nih.gov/pubmed/27118048
http://dx.doi.org/10.1186/s12967-016-0838-4

Ejemplares similares